Skip to main content

Table 1 Participant demographics by group

From: Tau-PET pathology in the subregions of the amygdala and its associations with cognitive performance and neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease

 

Non-Carriers (n = 37)

Unimpaired Carriers (n = 25)

P-value

Age (years)

35.8 [31.3 – 38.8]

35.8 [31.8 – 40.3]

0.763

Education (years)

11.0 [8.0 – 14.0]

11.0 [6.0 – 12.0]

0.181

Sex

  

1.000

 Female

20 (54%)

14 (56%)

 

 Male

17 (46%)

11 (44%)

 

Amyloid status

  

 < 0.001

 PiB-

37 (100%)

8 (32%)

 

 PiB+

0

17 (68%)

 

MMSE

29.0 [28.0 – 30.0]

28.0 [28.0 – 29.0]

0.018

FAST

  

0.052

 1

35 (95%)

19 (76%)

 

 2

2 (5%)

6 (24%)

 

CERAD Word List Learning

20.0 [19.0 – 23.0]

19.0 [16.0 – 21.0]

0.023

CERAD TMT-B Time

78.0 [56.0 – 103.0]

99.0 [54.0 – 138.0]

0.166

GDS-15

0.0 [0.0 – 2.0]

0.0 [0.0 – 2.0]

0.719

GAI-30

1.0 [0.0 – 3.0]

1.0 [0.0 – 6.0]

0.411

  1. Continuous variables represented as median [interquartile range] and compared across groups using Wilcoxon rank sum tests; and categorical variables represented as n (%) and compared across groups using Fisher’s exact tests
  2. CERAD Consortium to Establish a Registry for Alzheimer’s Disease, FAST Functional Assessment Staging Tool, GAI Geriatric Anxiety Inventory, GDS Geriatric Depression Scale, MMSE Mini Mental State Examination, PiB 11C-Pittsburgh compound B, TMT-B Trail Making Test Part B
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193